Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01874613
Other study ID # T97/2011
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 13, 2012
Last updated February 18, 2015
Start date January 2013
Est. completion date December 2019

Study information

Verified date February 2015
Source Turku University Hospital
Contact n/a
Is FDA regulated No
Health authority Finland: National Supervisory Authority for Welfare and Health
Study type Interventional

Clinical Trial Summary

Bioactive fibre-reinforced composite implant is used for reconstruction of skull bone defects and orbital floor defects.

Functional and aesthetic outcome is assessed by patient and doctor.


Description:

Development phase: Clinical trial Objectives: Assessment of functional and aesthetic outcome Methodology: Intervention study Sample size: 35+20+25 Main criteria for inclusion: Skull bone defect OR orbital floor fracture

Investigational drug/treatment, dose and mode of administration: FRC implant Comparative drug(s)/placebo/treatment, dose and mode of administration: -

Duration of treatment: 2 years of follow-up

Assessments:

Clinical outcome and radiologic assesment Functional and aesthetic outcome with Visual Analog Scale (VAS). Pain assessment with VAS.

Statistical methods:

Adequate statistical methods for publishing in international peer-reviewed journals.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 19
Est. completion date December 2019
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

Study arm 1:

- patients with skull bone defect

- reconstruction indications fullfilled

Study arm 2:

- patients with orbital floor defect

- reconstruction indication fullfilled

Exclusion Criteria:

- if informed consent cannot be obtained

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
FRC implant reconstruction
A cranioplasty with the FRC implant is performed.
FRC implant reconstruction
The orbital floor fracture is reconstructed with the FRC implant.

Locations

Country Name City State
Finland Department of Otorhinolaryngology Turku N/A = Not Applicable

Sponsors (3)

Lead Sponsor Collaborator
Turku University Hospital Oulu University Hospital, Turku Clinical Biomaterials Centre

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional outcome (a composition of following measures) After reconstruction, patient follow-up protocol follows to assess functional outcome, including safety.
Follow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.
Visual and manual assessment is done by a doctor. Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.
C-reactive protein level and leukocyte level is measured to assess the possible inflammation.
2 year follow-up Yes
Secondary Aesthetic outcome (a composition of following measures) After reconstruction, patient follow-up protocol follows to assess aesthetic outcome.
Follow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.
Visual and manual assessment is done by a doctor. Visual Analog Scale (VAS) is used by patient to assess
functional outcome
aesthetic outcome
pain Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.
C-reactive protein level and leukocyte level is measured to assess the possible inflammation.
2 years post-operatively No